MS, University of Cincinnati, 2014, Pharmacy: Pharmaceutical Sciences
OBJECTIVE: The objective of this study is to determine economic impact of body mass index (BMI) on clinical outcomes in adult renal transplant recipients.
RATIONALE: Worse patient outcomes have been reported in renal transplant recipients with lower and elevated BMI; however, the economic consequences associated with BMI on renal transplantation have not been reported. Quantifying costs of BMI and the impact on renal transplant outcomes would allow for future cost-effective analyses to be conducted.
METHODS: Data was obtained from a merged database of UNOS renal transplant registry and Medicare claims; collected by USRDS. Eligibility includes adult (>16) primary deceased and living donor kidney transplant recipients with BMI at transplantation and in which Medicare is the primary payer. BMI is categorized as WHO guidelines. Total direct medical costs related to patient morbidity and mortality and allograft function and survival will be assessed. Costs will be taken from the health-system perspective and will be standardized to 2012 dollars.
RESULTS: After application of exclusion criteria and data validation, of the 22,616 deceased donor and 7,373 living kidney transplant recipients were evaluated, BMI was a significant predictor of cost up to 6 months post-transplant compared to the base patient case. On multivariable analysis, BMI categories > 35 were attributed to significantly higher charges for deceased donor recipients. We found at a BMI 35-39.9 there was a significant difference in charges at transplant, 1, 3, and 6 months of $4,107 (p=0.005), $1,327 (p=0.008), $1,127 (p=0.005) and $1,214 (p=0.009) respectively. For BMI > 40 there was a significant difference in charges at transplant, 1, 3, and 6 months of $13,662 (P<0.001), $3,061 (p=0.002), $2,835 (p<0.0001), $1,935 (p=0.031), respectively. Average 3-year accumulated charges were $14,874 and $51,922 higher for a BMI of 35-39.9 and BMI > 40.
In living donor recipients, charges for B (open full item for complete abstract)
Committee: Jill Boone Pharm.D. (Committee Chair); Mark Eckman M.D. (Committee Member); Paul Volek M.P.H. (Committee Member); Teresa Cavanaugh Pharm.D. (Committee Member); Pamela Heaton Ph.D. (Committee Member)
Subjects: Health Sciences